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Background: Systemic sclerosis (SSc) is a connective tissue fibrotic disease for which there is no effective
treatment. Traditional Chinese Medicine (TCM), such as the Yiqihuoxue formula used in Shanghai TCM-integrated
Hospital, has shown the efficacy of anti-fibrosis in clinical applications. This study was aiming to dissect the anti-fibrotic
mechanism of Yiqihuoxue treatment for SSc.
Methods: Bleomycin-induced mice and SSc dermal fibroblasts were treated with Yiqihuoxue decoction; NIH-3T3
fibroblasts were exposed to exogenous TGF-β1, and then cultured with or without Yiqihuoxue decoction. Luciferase
reporter gene assay was used to determine the activity of Smad binding element (SBE). Quantitative reverse
transcription-polymerase chain reaction (RT-PCR) was used to examine the mRNA levels of extracellular matrix (ECM)
genes. The protein levels of type I collagen, Smad3 and phosphorylated-Smad3 (p-Smad3) were detected by western
blotting. Student’s t-tests were used to determine the significance of the results.
Results: Bleomycin-induced mice, SSc dermal fibroblasts and TGF-β1-induced NIH/3T3 fibroblasts showed higher levels
of ECM gene transcriptions and collagen production. In addition, the phosphorylation level of Smad3 and activity of
SBE were significantly increased after exogenous TGF-β1 induction. Whereas, Yiqihuoxue treatment could obviously
attenuate fibrosis in bleomycin-induced mice, down regulate ECM gene expressions and collagen production in SSc
dermal fibroblasts and TGF-β1-induced NIH/3T3 fibroblasts. Furthermore, the aberrantly high phosphorylation level of
Smad3 and activity of SBE in the TGF-β1-induced NIH/3T3 fibroblasts were also dramatically decreased by Yiqihuoxue
treatment.
Conclusions: Yiqihuoxue treatment could effectively reduce collagen production via down-regulating the phosphorylation
of Smad3 and then the activity of SBE, which are involved in the TGF-β pathway and constitutively activated in the
progression of SSc.
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Systemic sclerosis (SSc) is a connective tissue disease
mainly characterized by extensive fibrosis in skin and
internal organs, such as lung, heart, esophagus and kidney,
among which skin fibrosis is the universal manifestation
in SSc [1,2]. Previous reports have shown that SSc confers
a mortality risk and fibrosis of internal organs is the
leading cause of death in SSc patients [3,4]. Until
now, the precise mechanisms of skin fibrosis in SSc
remain unclear, and there are no generally accepted
and effective medical treatments for fibrosis.
Fibrosis is usually caused by the excessive production,
deposition and contraction of extracellular matrix (ECM)
components, especially collagen [5]. Fibroblast is the
principal cell type responsible for turnover and composition
of ECM. The “activated” fibroblast and its contractile and
secretory counterpart, myofibroblast, are the primary cell
types responsible for the persistent production and
deposition of ECM. Tissue injury initiates the chronic
inflammation generally involving the activation of
inflammatory and immune cells which secrete cytokines,
chemokines and growth factors. Then resident fibroblasts
(quiescent fibroblasts), pericytes, fibrocytes, epithelial
and endothelial cells are recruited, activated and finally
differentiated into myofibroblasts. The “activated” fibro-
blast is an intermediate stage between resident fibroblast
and myofibroblast. In addition, the “activated” fibroblast
and myofibroblast also produce cytokines and growth
factors such as TGF-β and CTGF to support further
fibrogenesis [6-8].
TGF-β is an important regulator in collagen production,
and normal fibroblasts stimulated by TGF-β displayed
features of SSc fibroblasts [9,10]. Previous research
suggested that the aberrant expression of TGF-β led
to the activation of ECM synthesis and dysfunction of
ECM degradation simultaneously [11], resulting in the
unbalance between ECM production and degradation
and thus fibrosis. Although the precise mechanism of
fibrosis in SSc remains unknown, those results suggest a
potential clue to uncover it. Latent TGF-β is cleaved to
release active TGF-β, then TGF-β binds to the type II
TGF-β receptor (TGFBRII) and activates the type I TGF-β
receptor (TGFBRI). Activated TGFBRI transduces signals
to the Smad proteins, that is, phosphorylates Smad3. The
phosphorylation of Smad3 allows it to form a heterodimer
with Smad4, which translocates into nucleus and interacts
with Smad binding element (SBE) in the promoter origin
of the target genes, resulting in the induction of gene
expressions including ECM genes [12-14]. Smad3 seems to
be a key signal transducer involved in the Smad-dependent
TGF-β signaling pathway. Indeed, Smad3-deficient mice
exhibited attenuated lung fibrosis induced by bleomycin
[15], and overexpression of Smad3 significantly increased
the activity of type I collagen promoter [16].CTGF is a key effector in the downstream of TGF-β and
plays a role in the regulation of fibroblast proliferation and
migration as well as TGF-β-dependent ECM production
[17]. In addition, Ctgf siRNA also ameliorated fibrosis in
skin and reduced inflammation in lungs of bleomycin-
induced mice [18]. SPARC, secreted protein, acidic and rich
in cysteine, is one of the major components in ECM.
Elevated expression of SPARC has been reported in numer-
ous animal models of fibrotic diseases and human fibrotic
tissues [19]. Furthermore, our previous work and others’
also showed SPARC siRNA effectively reduced fibrosis in
SSc dermal fibroblasts, TGF-β1-stimulated fibroblasts, skin
and lung tissues from bleomycin-induced mice [18,20,21].
It is thorny and challenging to find an effective therapy
for SSc, because of its complicated interaction of vascular,
immunologic and fibrotic components. Traditional Chinese
medicine (TCM) has a long history of dealing with diseases
for several thousand years. More importantly, TCM with
combinations of various components and multiple drug
targets shows an overwhelming advantage of treating com-
plicated diseases, such as acute promyelocytic leukemia
(APL) [22]. Currently, TCM has been applied to treat SSc
patients in many hospitals in China. The prescription of
Yiqihuoxue formula provided by the Shanghai TCM-
integrated Hospital has been shown a satisfactory capability
of attenuating SSc-associated fibrosis in clinical applica-
tions. The two main constituents of Yiqihuoxue formula
are Astragalus membranaceus and Salvia miltiorrhiza,
which have been proven effective in treating diseases. Com-
pound Astragalus and Salvia miltiorrhiza extract could
attenuate liver fibrosis induced by carbon tetrachloride via
inhibiting Smad2 phosphorylation and α-SMA expression
[23]; a standardized extract from Paeonia lactiflora and
Astragalus membranaceus exerted an anti-fibrotic effect in
rats induced by porcine serum via down-regulating
PDGFR-β, inhibiting HSC proliferation and MAPK activa-
tion [24]; constituents of Radix Salviae Miltiorrhizae inhib-
ited proliferation and procollagen synthesis in SSc dermal
fibroblasts [25]; one of the main active components from
Radix Salviae miltiorrihizae called Salvianolic Acid B could
attenuate liver fibrosis by inhibiting Angiotensin II signaling
[26]. In order for the modernization and generalization of
Yiqihuoxue formula in treating SSc, the precise anti-fibrotic
mechanism remained to be addressed by using molecular
approaches.
Aiming to explore the underlying mechanism of TCM
in treatment of SSc-associated fibrosis, we used the
treatment of Yiqihuoxue formula in vivo and in vitro in
the present study.
Methods
Composition and preparation of Yiqihuoxue formula
Yiqihuoxue formula was obtained from the Shanghai
TCM-integrated Hospital and the full components are
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sinensis, Caulis spatholobi, Semen persicae, Tuyuan,
Agkistrodon piscivorus, Centella asiatica, Ganoderma
lucidum, Herba epimedii, Poria peel and Radix glycyrrhizae,
of which Astragalus membranaceus and Salvia miltiorrhiza
are two major components. The Yiqihuoxue decoction
was boiled with ultrapure water as the doctor’s directions.
In in vivo study, 250 μl Yiqihuoxue decoction was fed to
mice twice a day at the concentration of 23 g/d/kg. In
in vitro study, it was filtered through a filter membrane
in 0.22 μm and diluted to the concentration of
10 mg/ml in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen, Carlsbad, CA, USA) with 10%
fetal calf serum (FCS, Invitrogen).
Cell culture
Skin biopsy specimens were obtained from three diffuse
SSc patients, who were fulfilled the American College of
Rheumatology (formerly, the American Rheumatism
Association) criteria for SSc [14]. Skin biopsy specimens
were collected from three normal controls who had no his-
tory of autoimmune and other dermal diseases. All patients
provided written contents, and the study was approved by
the School of Life Sciences, Fudan University, China.
Skin samples were transported in DMEM supplemented
with 10% FCS for processing the same day. The skin
samples were washed in 75% ethanol, phosphate buffered
saline (PBS), and DMEM with 10% FCS. Cultured fibroblast
strains were established by mincing tissues and placing
them into 60-mm culture dishes secured by glass cover-
slips. Third- to fifth-passage human dermal fibroblasts were
placed into 12-well culture plates at the density of 1 × 105
cells per well for gene and protein expression assays.
Bleomycin-induced dermal fibrosis mouse model
establishment
Specific pathogen-free (SPF) mice on a C57BL/6 back-
ground were purchased from Sino-British Sippr/BK Lab
Animal Ltd. (Shanghai, China). Skin fibrosis was induced in
7-week-old female mice by administering local injections of
bleomycin for 3 weeks. Briefly, bleomycin dissolved in
filter-sterilized saline at a concentration of 200 μg/ml,
and 100 μl of bleomycin was administered daily by
subcutaneous injection into defined areas of 1 cm2 on
the upper back. Subcutaneous injections of 100 μl saline
were used as controls. After 3 weeks, the mice were killed
by chloral hydrate anesthesia and skin tissues were
harvested in order to analyze gene and protein expression
levels. All the animal protocols were approved by the
School of Life Sciences, Fudan University, China.
Drug administration regimens
Mice were randomly divided into two groups. As de-
scribed in Figure 1(1), the first group (Prevention, P)received Yiqihuoxue decoction daily at the same time as
bleomycin administration for 3 weeks. The second group
(Prevention & Treatment, P & T) received Yiqihuoxue
decoction for another 2 weeks compared with the first
group. Four mice were used in each group.Preparation and treatment of recombinant TGF-β1
and TCM
Recombinant TGF-β1 was purchased from R&D Systems
(Minneapolis, MN, USA) and diluted to the concentration
of 10 ng/μl in DMEM medium with 1% FCS. SSc dermal
fibroblasts were placed into a 12-well culture plate at the
density of 1 × 105 cells per well and cultured for 24 hours
followed by treatment with or without Yiqihuoxue decoc-
tion (10 mg/ml). These cells were then examined 24 hours
later for gene and protein expressions. NIH/3T3 fibroblasts
were also seeded at the same density as SSc fibroblasts and
cultured with or without TGF-β1 (10 ng/μl) for 24 hours
after starved overnight. Then the culture medium was
replaced by the normal medium with or without Yiqihuoxue
decoction (10 mg/ml) and examined 24 hours later for
gene and protein expressions.Luciferase reporter gene assay
pGL3-SBE4-Luc was a gift from Dr. Kiyoshi Higashi
(Sumitomo Chemical Co., Ltd., Osaka, Japan), which
consisted of four short tandem repeats of Smad binding
element (SBE) (GTCTAGAC) with a minimal promoter
(TATA box).The plasmid of pRL-SV40 was used as an
internal control. NIH/3T3 fibroblasts were placed into a
24-well culture plate, and then 500 ng of pGL3-SBE4-Luc
or pGL3-Basic plasmid were co-transfected with 10 ng of
pRL-SV40 per well using Lipofectamin 2000 (Invitrogen)
according to the manufacturer’s protocol. After 6 hours’
transfection, the culture medium was replaced by TGF-β1
medium with or without Yiqihuoxue decoction. Cell
lysates were harvested 24 hours later and luciferase activity
assay was performed according to the manufacturer’s
protocol of Dual-luciferase reporter assay system (Promega,
Madison, WI, USA) with a GloMax 20/20 Luminometer
(Promega).Preparation and phosphorylation assay
Antibodies to Smad3 and p-Smad3 were purchased from
Cell Signaling Technology Inc. (Beverly, MA, USA).
NIH/3T3 fibroblasts were placed into a 12-well culture
plate at the density of 1 × 105 cells per well and grown
until confluency. The culture medium was added by
Yiqihuoxue decoction and cultured for 24 hours. After
that, NIH/3T3 fibroblasts were treated with TGF-β1 for
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Figure 1 Gene expressions and examination of skin tissues from bleomycin-induced mice with different treatments. (1) Drug
administration regimens for mouse model establishment. B, bleomycin; P, prevention group; P & T, prevention & treatment group. (2) Relative
transcript levels of Col1a2, Col3a1 and Ctgf in skin tissues from bleomycin-induced mice with different treatments in P and P & T group. Sa, saline;
B, bleomycin; Y, Yiqihuoxue decoction. A. P group; B. P & T group. The expression level of each gene in saline-treated mice was normalized to
1. *, P <0.05; **, P <0.001. (3) Representative histological analysis of HE and Masson’s trichrome staining of mouse skin tissues with different treatments
in high magnifications (100 ×). Four mice were used for each group. A. P group; B. P & T group; C, D, results of analysis of dermal thickening from skin
tissues from mouse models with different treatments in P and P & T group, respectively. Bars showed the mean ± SD results of analysis of four mice.
*, P <0.05; **, P <0.001.
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reaction (RT-PCR)
RT-PCR was performed using an ABI Prism 7900 Detector
Sysyem (Applied Biosystems, Foster City, CA, USA). The
specific primers for each gene were designed using Primer
5 and synthesized by Generay Biotech Co., Ltd. (Shanghai,
China). Total RNA samples were extracted from the
cultured fibroblasts using TRIzol reagent (Invitrogen).
Complementary DNA (cDNA) was synthesized using
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). RT-PCR was performed using SYBR Premix
ExTaq from TaKaRa Biotechnology Co., Ltd (Dalian,
China). The data obtained from the assays were analyzed
with SDS 2.3 software (Applied Biosystems). The amount
of total RNA in each sample was normalized with
GAPDH/Gapdh transcription levels.
Western blotting analysis
The protein concentration was determined using BCA
protein assay kit (Beyotime Institute of Biotechnology,
Shanghai, China). Equal amount of proteins from each sam-
ple was subject to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) on a 10% polyacrylamide
gel. Resolved proteins were transferred onto a polyvinylide-
nedifluoride (PVDF) membrane (Millipore, Billerica, MA,
USA), and then blocked for 1 hour at room temperature
using Tris Buffered Saline Tween (TBST) with 5% Bull
Serum Albumin (BSA). After that, blotted proteins were
incubated at 4°C overnight with a 1:1000 dilution of anti-
mouse collagen antibody (Millipore), anti-Smad3 antibody
(Cell Signaling Technology), and anti-p-Smad3 antibody
(Cell Signaling Technology), as well as 1:500 dilution of
anti-human collagen antibody (Millipore), respectively.
Anti-GAPDH antibody (Cell Signaling Technology) was
used as an internal control. After three washes with
TBST for 30 minutes, the blotted proteins were incubated
with the secondary antibody for 1 hour at room temp-
erature, which was horse-radish peroxidase-conjugated
anti-mouse, anti-rabbit or anti-goat IgG. Specific proteins
were detected using an enhanced chemiluminescence
system (Thermo Fisher Scientific Inc., Waltham, MA,
USA), and the intensity of bands was quantified using
ImageQuantTL software (General Electric Company,
Fairfield, CT, USA).Histological analysis
For the assessment of histopathological changes, skin
tissues were embedded in paraffin after fixed with 4%
paraformaldehyde. Then 4 um-thick skin sections were
stained with hematoxylin/eosin or Masson’s trichrome
staining for better visualization of the tissue structure.
Dermal thickness was analyzed with a Nikon Eclipse
80i microscope (Nikon, Badhoevedorp, The Netherlands) by
measuring the maximal distance between the epidermal–
dermal junction and the dermal–subcutaneous fat junction
at 4 different skin sections in each mouse, as previously
described [27]. Hypodermal thickness was determined by
measuring the thickness of the subcutaneous connective
tissue beneath the panniculus carnous at 4 different sites of
the upper back in each mouse. The evaluation was
performed by 2 independent examiners.
Results
Yiqihuoxue treatment ameliorated skin fibrosis in
bleomycin-induced mouse models
In this study, bleomycin-induced skin fibrosis mouse
models were used to evaluate the anti-fibrotic effect of
TCM treatment. Mice were randomly divided into
two groups as described in Figure 1(1): Prevention (P)
group and Prevention & Treatment (P & T) group.
As measured by quantitative real-time RT-PCR, the
transcripts of Col1a2, Col3a1, and Ctgf in both groups
showed increased expressions in the skin tissues from
bleomycin-induced mice, and Yiqihuoxue treatment re-
covered them nearly to the normal levels (Figure 1(2)).
Moreover, the most significant effects of bleomycin and
Yiqihuoxue treatment were detected in the P & T group,
i.e., the fold changes of each gene in the skin tissues
from bleomycin-induced mice were 5.3 ± 1.7-folds for
Col1a2 (P = 0.016), 4.1 ± 0.4-folds for Col3a1 (P = 0.037),
and 3.7 ± 1.5-folds for Ctgf (P = 0.007), respectively. After
Yiqihuoxue treatment, significant reductions of Col1a2
(74.2% with P = 0.020), Col3a1 (67.1% with P = 0.031), and
Ctgf (49.9% with P = 0.037) were found (Figure 1-2B). HE
stain of skin tissues (Figure 1(3)) showed a significant der-
mal thickening after the induction of bleomycin in P & T
group (P = 0.028), compared with the saline injection
group. After Yiqihuoxue treatment, dermal thickening was
notably improved (P = 0.024). Attenuation of dermal
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tration, though not very significant. Masson’s trichrome
(Figure 1(3)) results were consistent with those of HE
stain. Therefore, Yiqihuoxue treatment could significantly
attenuate fibrosis and displayed an anti-fibrotic role in the
treatment of SSc. More interestingly, Yiqihuoxue treat-
ment not only exerted a powerful therapeutic action, but
also presented a potential preventive effect in treating SSc.
Elevated expressions of ECM genes and excessive
collagen production in cultured fibroblasts from the skin
tissues of patients with SSc
Fibroblasts play a primary role in the collagen production of
SSc. RT-PCR data showed ECM genes including COL1A2,
COL3A1, CTGF, SPARC and TGF-β1 showed constitutive
over-expressions in the SSc dermal fibroblasts compared
with those in the healthy controls (Figure 2A). The fold
changes of each gene in the SSc fibroblasts were 3.1 ± 0.85-
folds (P = 0.003) for COL1A2, 6.7 ± 0.59-folds (P < 0.001) for
COL3A1, 2.4 ± 0.28-folds (P < 0.001) for CTGF, 26.4-folds ±
1.91 (P < 0.001) for SPARC and 31.1 ± 4.19-folds (P < 0.001)
for TGF-β1, respectively. Western blotting analysis showed
a similar tendency of higher protein levels of type I collagen.
Thus, fibroblasts were highly activated and synthesized
abundant collagen proteins during the progress of SSc.
Yiqihuoxue treatment reduced type I collagen production
in the cultured fibroblasts from the skin tissues of
patients with SSc
As shown in Figure 3A, significant reductions of COL1A2
(49.8% with P = 0.012) and COL1A3 (59.6% with P = 0.047)A
B C
Figure 2 Gene expressions and collagen production between SSc der
COL1A2, COL3A1, CTGF, SPARC and TGF-β1 in three SSc dermal fibroblasts and
was normalized to 1. *, P <0.05; **, P <0.001. SF, SSc dermal fibroblast; NF, nor
(COL1) in the three SSc dermal fibroblasts and normal dermal fibroblasts. (C)
Bars showed the mean ± SD results of three paired fibroblast strains (normal awere observed after Yiqihuoxue treatment. In addition,
other ECM genes including CTGF, SPARC and TGF-β1
were also down-regulated by Yiqihuoxue treatment.
Results of western blotting (Figure 3B, 3C) also
showed a significant reduction of type I collagen with
Yiqihuoxue treatment (32.6% with P = 0.040). Thus,
Yiqihuoxue treatment could attenuate fibrosis by
weakening the capacity of collagen production in
fibroblasts.
Yiqihuoxue treatment attenuated type I collagen
production stimulated by exogenous TGF-β1 in the
NIH/3T3 fibroblasts
To clarify the mechanism of anti-fibrotic efficacy in
Yiqihuoxue treatment in vitro, we utilized the cell line
of NIH/3T3 fibroblasts to establish an in vitro model
in this study. Results of RT-PCR (Figure 4A) showed
that the transcript levels of Col1a2 and Col3a1 were
dramatically increased (16.1 ± 2.99-folds and 1.7 ± 0.14-folds,
respectively) after the stimulation of exogenous TGF-β1,
and exhibited an SSc-like phenotype. In parallel, the
transcript levels of Ctgf, Sparc and Tgf-β1 were also
highly elevated by 10.7 ± 1.21-folds to 46.0 ± 3.27-folds,
respectively. However, Yiqihuoxue treatment attenu-
ated fibrosis induced by exogenous TGF-β1 and re-
stored those gene expressions almost to the normal
levels. Western blotting analysis also indicated that type I
collagen production was highly activated by exogen-
ous TGF-β1 (60.0% increase with P = 0.022), while
decreased by 33.2% (P = 0.002) after TCM treatment
(Figure 4B, 4C).mal fibroblasts and normal controls. (A) Relative transcript levels of
normal controls. The expression level of each gene in normal controls
mal dermal fibroblast. (B) Western blotting analysis of type I collagen
Densitometric analysis of western blotting for type I collagen (COL1).
nd SSc). *, P <0.05; **, P <0.001.
AB C
Figure 3 Gene expressions and collagen production between SSc dermal fibroblasts with or without Yiqihuoxue treatment. (A) Relative
transcript levels of COL1A2, COL3A1, CTGF, SPARC and TGF-β1 in three SSc dermal fibroblasts with or without Yiqihuoxue treatment. N, non-treated; Y,
Yiqihuoxue decoction. The expression level of each gene in non-treated group was normalized to 1. *, P <0.05; **, P <0.001. (B) Western blotting analysis
of type I collagen (COL1) in the three SSc dermal fibroblasts with or without Yiqihuoxue treatment. (C) Densitometric analysis of western blotting for type
I collagen (COL1). Bars showed the mean ± SD results of three assays. *, P <0.05; **, P <0.001.
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production via down-regulating the phosphorylation level
of Smad3 and then the activity of SBE in the type I
collagen promoter
Numerous researches have revealed that TGF-β signaling
pathway plays a pivotal role in the fibrogenesis of SSc [28].
Furthermore, Smad binding element (SBE) is located
in the type I collagen promoter, which mediates theA
B C
Figure 4 Gene expressions and collagen production in NIH/3T3 fibrob
(A) Relative transcript levels of Col1a2, Col3a1, Ctgf, Sparc and Tgf-β1 in mu
Y, Yiqihuoxue decoction. The expression level of each gene in non-treated
(B) Western blotting analysis of type I collagen (COL1) in murine 3T3 fibrob
blotting for type I collagen (COL1). Bars showed the mean ± SD results of ttranscriptional up-regulation stimulated by TGF-β
together with the adjacent Sp-1 binding site [29]. To
clarify the mechanism by which Yiqihuoxue treatment
reduced collagen production, we conducted luciferase
reporter gene assay. As shown in Figure 5A, the activity of
SBE in the type I collagen promoter significantly increased
by 19.8 ± 1.49-folds (P = 0.031) after the stimulation of ex-
ogenous TGF-β1, however, Yiqihuoxue treatment restoredlasts with or without TGF-β1 and/or Yiqihuoxue treatment.
rine 3T3 fibroblasts with different treatments. N, non-treated; T, TGF-β1;
murine 3T3 fibroblasts was normalized to 1. *, P <0.05; **, P <0.001.
lasts with different treatments. (C) Densitometric analysis of western
hree assays. *, P <0.05; **, P <0.001.
AB C
Figure 5 Relative activity of SBE and phosphorylation of Smad3 in NIH/3T3 fibroblasts with different treatments. (A) Relative activity of
SBE in the region of type I collagen promoter in murine 3T3 fibroblasts with different treatments. N, non-treated; T, TGF-β1; Y, Yiqihuoxue decoction.
The relative activity of SBE in non-treated murine 3T3 fibroblasts was normalized to 1. *, P <0.05; **, P <0.001. (B) Western blotting analysis of p-Smad3
and Smad3 in murine 3T3 fibroblasts with different treatments. p-Smad3, phosphorylated-Smad3. (C) Densitometric analysis of western blotting for
p-Smad3 and Smad3. Bars showed the mean ± SD results of three assays. *, P <0.05; **, P <0.001.
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particularly Smad3, are considered as important signal
transducers in the TGF-β signaling pathway. Moreover,
the phosphorylation of Smad proteins could transduce
signals and activate gene transcriptions in the downstream
of TGF-β signaling pathway. To further investigate whether
the phosphorylation of Smad3 contributed to the reduction
of SBE activity, this study subsequently detected the
phosphorylation levels of Smad3 after the stimulation of
exogenous TGF-β1 with or without Yiqihuoxue treatment.
As illustrated in Figure 5B and C, p-Smad3 was remarkably
increased after the stimulation of exogenous TGF-β1
(5.5 ± 0.05-folds with P < 0.001), however, a lower phos-
phorylation level of Smad3 appeared after Yiqihuoxue
treatment (60.5% decrease with P =0.001). Consequently,
Yiqihuoxue treatment reduced collagen production via
decreasing the phosphorylation level of Smad3 and
inhibiting the interaction of Smad3/4 complex with
SBE in the type I collagen promoter.
Discussion
SSc is a typical chronic fibrotic disease with multiple-
system involvement, mainly including skin and various
visceral organs such as lung, heart, esophagus and kidney.
Its etiology remains to be unveiled so far. Currently,
principal medical therapies for SSc are still restricted
to certain immunomodulatory and anti-fibrotic agents,
such as glucocorticoid, colchicine and cyclophosphamide,
which are used to treat symptoms of SSc with limitedtherapeutic effects. What is worse, side effects of these
medications undoubtedly add to the burden of patients’
lives in general. Applications of TCM to treat diseases
have a long history in China. Based on compatible princi-
ples of Chinese Medicine and symptoms of patients, TCM
formula is usually composed of several herbs or minerals,
which can exert a comprehensive effect on the diseases.
Although working slowly, it is mild and less harmful to
the quality of patients’ lives. In China, TCM treatments
have been applied to treat SSc patients by many hospitals,
among which Yiqihuoxue formula is a good example
and has been proven an anti-fibrotic efficacy in clinical
applications. Therefore, it is imperative to gain a better
understanding of the mechanism of TCM as an effective
anti-fibrotic treatment for SSc.
In the progress of SSc, vascular dysfunction, auto-
immunity and inflammation may jointly contribute to
the fibrogenesis [6]. Salvia miltiorrhiza is one of the
main herbs in Yiqihuoxue formula, and its active
component, salvianolic acid, has the function of removing
blood stasis to improve vascular dysfunction [30,31].
Several researches indicated that salvianolic acid B (SAB)
could attenuate liver fibrosis via TGF-β-related signaling
pathways [32,33], and SAB addition inhibited Smad3
protein expression and its nuclear translocation in hepatic
stellate cells [34]. In this study, we also found that
Yiqihuoxue treatment could significantly reduce the
phosphorylation level of Smad3 and the activity of SBE
(Figure 5), so that we assumed that Salvia miltiorrhiza in
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Smad-dependent TGF-β signaling pathway. In addition,
Astragalus membranaceus is also one of the main compo-
nents in Yiqihuoxue formula, and useful for immune
enhancement and anti-inflammation [35,36]. Astragalus
membranaceus has been used in TCM for thousands of
years. In modern Chinese Medicine, it has been used for
cardiovascular and immunity system improvement [37,38].
The related constituents from Astragalus membranaceus
exhibited an anti-inflammatory effect by the inhibitory ac-
tivity of NF-kB [39], whose inhibition could also down-
regulate the expression of CTGF in SSc fibroblasts [40].
Here, we proposed that Astragalus membranaceus attenu-
ated fibrosis because of its immunomodulatory and anti-
inflammatory properties. However, the precise mechanism
of TCM treatment for vascular and immune system
improvement remains unclear and deserves further efforts.
More interestingly, we also found that the absence of
the two animal products in Yiqihuoxue formula, Tuyuan
and Agkistrodon piscivorus, had no effects on decreasing
SBE activity and Smad3 phosphorylation in the TGF-β1-
treated NIH/3T3 fibroblasts (Additional file 1: Figure S1),
indicating that these two animal components were not the
necessary parts of the treatment formulation for systemic
sclerosis, which meant that Yiqihuoxue formula had some
redundancies. Thus, studies on the isolation of active
ingredients and optimization of treatment formulation will
greatly benefit the broader prospect for Yiqihuoxue for-
mula and other traditional Chinese medical treatment.
Fibrosis is the main and most universal manifestation
of SSc, which is caused by the unbalanced state between
ECM production and degradation. TGF-β is considered as
a potent profibrotic cytokine involved in the pathogenesis
of SSc, because of its fibrotic functionality of stimulation of
ECM synthesis and inhibition of metalloproteinase produc-
tion [13]. Type I and type III collagens are two major pro-
teins in the ECM components. CTGF is an important
downstream cytokine which is regulated by TGF-β and has
a synergistic effect with TGF-β [41,42]. In this study, over-
expressions of both type I and type III collagen, and other
ECM genes such as CTGF/Ctgf, SPARC/Sparc, TGF-β1/
Tgf-β1 were observed in bleomycin-induced mice, SSc
dermal fibroblasts as well as TGF-β1-induced cell model
(Figures 1, 2, 4), however, Yiqihuoxue treatment could
recover them to the normal levels (Figures 1, 3, 4). Notably,
the effects of Yiqihuoxue formula on the bleomycin-treated
mice were more significant in the Prevention & Treatment
group compared with those in the Prevention group
(Figure 1), both in the reduction of ECM genes (Col1a2/
Col3a1/Ctgf) by TCM and histopathological changes. It
suggested that the effect of Yiqihuoxue formula was much
better when administrated for long-term treatment, and it
might exert its anti-inflammatory function in the early stage
and anti-fibrotic function in the later stage.Conclusions
Our studies preliminarily demonstrated that Yiqihuoxue
treatment for SSc significantly reduced collagen production
in both in vivo bleomycin-induced mouse models and
in vitro SSc dermal firbroblasts and TGF-β1-induced
NIH/3T3 fibroblasts, via down-regulating the phosphoryl-
ation of Smad3 and the activity of SBE in the type I colla-
gen promoter. Although our studies were limited to mouse
model and cell culture conditions, it was the first attempt
to explore the mechanism of TCM treatment for SSc,
which provided a valuable clue to find novel drug targets
and develop new medications for SSc.
Additional file
Additional file 1: Figure S1. Relative activity of SBE and phosphorylation
of Smad3 in NIH/3T3 fibroblasts with different treatments. (S1) Relative
activity of SBE in the region of type I collagen promoter in murine 3T3
fibroblasts with different treatments. N, non-treated; T, TGF-β1; Y, whole
Yiqihuoxue formula; Y−, Yiqihuoxue formula without Tuyuan; Y−1, Yiqihuoxue
formula without Agkistrodon piscivorus; Y−2, Yiqihuoxue formula without
both Tuyuan and Agkistrodon piscivorus. Bars showed the mean ± SD results
of three assays. *, P <0.05. (S2) Western blotting analysis of p-Smad3 and
Smad3 in murine 3T3 fibroblasts with different treatments.
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